X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.98−0.11 (-3.56%)
Close on Nov 18, 2026Market cap $295.46MP/E –Yield –
X4 Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
X4 Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $9.90M, up 73.7% year over year. For fiscal 2025 it was $6.50M, up 150.0% from the year before. The highest annual figure on record is $6.50M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50M | +150.0% |
| FY2024 | Dec 31, 2024 | $2.60M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $3.00M | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.80M | +75.0% |
| Q2 FY2026 | Jun 30, 2026 | $2.40M | +41.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.50M | +177.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.20M | +46.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.60M | +185.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.70M | +202.0% |
| Q1 FY2025 | Mar 31, 2025 | $900.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $1.50M | – |
| Q3 FY2024 | Sep 30, 2024 | $560.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $563.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $3.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $3.50M | – |
See a number that looks wrong?